Research ArticleArticle
Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients
MITSUKUNI SUENAGA, WU ZHANG, TETSUO MASHIMA, MARTA SCHIRRIPA, SHU CAO, SATOSHI OKAZAKI, MARTIN D. BERGER, YUJI MIYAMOTO, AFSANEH BARZI, TOSHIHARU YAMAGUCHI and HEINZ-JOSEF LENZ
Cancer Genomics & Proteomics May 2021, 18 (3) 317-324; DOI: https://doi.org/10.21873/cgp.20262
MITSUKUNI SUENAGA
1Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, U.S.A.;
2Gastroenterology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan;
3Department of Specialized Surgeries, Tokyo Medical and Dental University (TMDU), Tokyo, Japan;
WU ZHANG
1Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, U.S.A.;
TETSUO MASHIMA
4Division of Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan;
MARTA SCHIRRIPA
1Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, U.S.A.;
SHU CAO
5Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, U.S.A.
SATOSHI OKAZAKI
1Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, U.S.A.;
MARTIN D. BERGER
1Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, U.S.A.;
YUJI MIYAMOTO
1Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, U.S.A.;
AFSANEH BARZI
1Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, U.S.A.;
TOSHIHARU YAMAGUCHI
2Gastroenterology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan;
HEINZ-JOSEF LENZ
1Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, U.S.A.;
In this issue
Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients
MITSUKUNI SUENAGA, WU ZHANG, TETSUO MASHIMA, MARTA SCHIRRIPA, SHU CAO, SATOSHI OKAZAKI, MARTIN D. BERGER, YUJI MIYAMOTO, AFSANEH BARZI, TOSHIHARU YAMAGUCHI, HEINZ-JOSEF LENZ
Cancer Genomics & Proteomics May 2021, 18 (3) 317-324; DOI: 10.21873/cgp.20262
Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients
MITSUKUNI SUENAGA, WU ZHANG, TETSUO MASHIMA, MARTA SCHIRRIPA, SHU CAO, SATOSHI OKAZAKI, MARTIN D. BERGER, YUJI MIYAMOTO, AFSANEH BARZI, TOSHIHARU YAMAGUCHI, HEINZ-JOSEF LENZ
Cancer Genomics & Proteomics May 2021, 18 (3) 317-324; DOI: 10.21873/cgp.20262
Jump to section
Related Articles
- No related articles found.